The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

To evaluate the safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation (NVAF)and to obtain information on pharmacokinetics and pharmacodynamics (anti-thrombotic potential) in the target population

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Subjects are eligible for the study if all of the following apply:

Subject has paroxysmal permanent or persistent NVAF

Subject has INR of 2.0 or below and an aPTT ≤ 1.5 times the upper limit of normal at the baseline visit.

Legal minimum age requirement (country-specific).

Written informed consent has been obtained.

Exclusion Criteria:

History of heart valve disorders

History of rheumatic fever.

History of stroke and/or systemic embolism (including TIA).

History of Acute Coronary Syndrome (ACS).

Indication for warfarin other than NVAF.

Known hemorrhagic disorder and/or coagulation disorder.

Active bleeding or any condition associated with increased risk of bleeding.